<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0120-5633</journal-id>
<journal-title><![CDATA[Revista Colombiana de Cardiología]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. Colomb. Cardiol.]]></abbrev-journal-title>
<issn>0120-5633</issn>
<publisher>
<publisher-name><![CDATA[Sociedad Colombiana de Cardiologia. Oficina de Publicaciones]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0120-56332017000300230</article-id>
<article-id pub-id-type="doi">10.1016/j.rccar.2016.08.005</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Contrapulsación externa aumentada, un tratamiento no invasivo recomendado para la angina refractaria, valoración de la clase funcional y la calidad de vida]]></article-title>
<article-title xml:lang="en"><![CDATA[Enhanced external counterpulsation, a non-invasive therapy recommended for refractory angina. Functional class and quality of life]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Mendoza]]></surname>
<given-names><![CDATA[Fernán]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Jaramillo]]></surname>
<given-names><![CDATA[Claudia]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Poveda]]></surname>
<given-names><![CDATA[Marcela]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Gómez]]></surname>
<given-names><![CDATA[Efraín]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Martínez]]></surname>
<given-names><![CDATA[Silvia]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Canro]]></surname>
<given-names><![CDATA[Andrés Felipe]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Fundación Clínica Shaio  ]]></institution>
<addr-line><![CDATA[Bogotá ]]></addr-line>
<country>Colombia</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>06</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>06</month>
<year>2017</year>
</pub-date>
<volume>24</volume>
<numero>3</numero>
<fpage>230</fpage>
<lpage>240</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_arttext&amp;pid=S0120-56332017000300230&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_abstract&amp;pid=S0120-56332017000300230&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_pdf&amp;pid=S0120-56332017000300230&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Introducción:  La enfermedad coronaria es una causa importante de la morbilidad y la mortalidad en el mundo. Dentro de este grupo, se encuentran los pacientes con angina refractaria.  Objetivo:  El objetivo de la investigación fue evaluar la eficacia y seguridad de la contrapulsación externa aumentada con 35 sesiones de una hora, en una población atendida desde diciembre de 2013 hasta noviembre de 2015.  Materiales y métodos:  Se realizó un estudio observacional analítico de cohorte concurrente. Se seleccionaron los pacientes que fueron remitidos para contrapulsación. A todos se les realizó una evaluación incial y a los seis meses de la clase funcional de angina según la Canadian Cardiovascular Society y disnea de la New York Heart Association, se valoraron los medicamentos recibidos y procedimientos realizados. Se aplicó el cuestionario de calidad de vida EQ - 5 D antes y a los seis meses. Para establecer la presencia de diferencias en el seguimiento en la clase funcional, la calidad de vida al inicio y a los seis meses, se utilizó la prueba no paramétrica de Wilcoxon para datos pareados, con un nivel de significación menor de 0,05. Las estadísticas fueron analizadas con el programa SPSS versión 20,0.  Resultados:  El análisis inicial de 74 pacientes, 50 hombres (67,6%), el promedio de edad 65,5 años. Al inicio de la terapia el 74,4% de los pacientes, se encontraban con disnea clase II - III de la New York Heart Association y el 77% con angina II - III de la Canadian Cardiovascular Society. La mediana de la fracción de eyección fue 50,5% (35,0 - 60,0). Los antecedentes más importantes fueron: la hipertensión arterial 62 (83,8%) y la diabetes mellitus 28 (37,8%). Medicamentos recibidos para la angina y procedimientos realizados: betabloqueadores 74 (100%), estatinas 71 (95,9%), aspirina 67 (90,5%), inhibidores de la enzima convertidora de angiotensina/bloqueadores de los receptores de angiotensina 64 (86,5%), trimetazidina 56 (75,7%), nitratos 37 (50%), calcioantagonistas 20 (27%), ivabradina 15 (20,3%), revascularización quirúrgica 41 (55,4%), revascularización percutánea 51 (68,9%), rehabilitación cardiovascular 45 (60,8%) y uso de dispositivos como el marcapasos, el cardiodesfibrilador o el Cardiodesfibrilador con resincronizador 19 (25,6%). A los seis meses se analizaron 45 pacientes que habían terminado el tratamiento, encontrando que el 91,1% estaba en clase I - II de disnea de la New York Heart Association y el 93,2% clase I - II de angina de la Canadian Cardiovascular Society (p &lt; 0,01 para ambos). En la evaluación de la calidad de vida se revisaron 36 pacientes que llenaron el instrumento EQ - 5 D, encontrando una mejoría significativa en la variable de movilidad (p = 0,021) y en la escala visual análoga de salud, con una mediana inicial de 70,0 (RIQ: 50,0 - 80,0), que mejoró a los 6 meses a 80 (RIQ: 70,0 - 90,0), p = 0,003. No se encontraron complicaciones con la contrapulsación.  Conclusiones:  La terapia de contrapulsación externa aumentada, mejora la calidad de vida y la clase funcional de angina y disnea en pacientes con angina refractaria y se convierte en un procedimiento no invasivo seguro y eficaz.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Introduction:  Coronary disease is an important cause for morbidity and mortality worldwide. Within this group there are patients with refractory angina.  Objective:  The goal of this investigation was to assess efficiency and security of enhanced external counterpulsation (EECP) with 35 one-hour sessions, in a population assisted between December 2013 and November 2015.  Material and methods:  Analytical observational recurrent cohort study. Patients who were referred for counterpulsation were selected. All of them were assessed in the beginning and after six months of the functional class of angina according to the Canadian Cardiovascular Society (CCS) and dyspnoea to the New York Heart Association (NYHA). Medication received and the procedures carried out were evaluated. The EQ-5D quality of life questionnaire was applied before and after six months. In order to establish the presence of differences in the follow-up of the functional class, the quality of life in the beginning and after six months, the Wilcoxon nonparametric test for paired data was used, with a significance level below 0.05. Data were analysed using SPSS version 20.0.  Results:  Initial analysis of 74 patients, 50 men (67.6%), with an average age of 65.5 years. In the beginning of the therapy 74.4% of patients had class II - III dyspnoea (NYHA) and 77% class II - III angina (CCS). The median ejection fraction was 50.5% (35.0 - 60.0). The most important previous conditions were arterial hypertension 62 (83.8%) and diabetes mellitus 28 (37.8%). Medication received for angina and conducted procedures: betablockers 74 (100%), statins 71 (95.9%), aspirin 67 (90.5%), angiotensin-converting-enzyme inhibitors/angiotensin receptor antagonists 64 (86.5%), trimetazidine 56 (75.7%), nitrates 37 (50%), calcium antagonists 20 (27%), ivabradine 15 (20.3%), surgical revascularisation 41 (55.4%), percutaneous revascularisation 51 (68.9%), cardiovascular rehabilitation 45 (60.8%) and use of devices such as pacemakers, implantable cardioverter-defibrillators (CDI) or ICDs with synchronizers 19 (25.6%). After six months 45 patients who had finished the treatment were analysed, revealing that 91.1% was in class I - II dyspnoea (NYHA) and 93.2% were class I - II angina (CCS) (p &lt; 0.01 for both). For the quality of life assessment 36 patients who has filled out the EQ-5D were reviewed, thus finding a significant improvement in the mobility variable (p = 0.021) and the visual analogue scale, with an initial median of 70.0 (RIQ: 50.0 - 80.0), that improved after six months to 80 (RIQ: 70.0 - 90.0), p = 0.003. No complications for counterpulsation were found.  Conclusions:  Enhanced external counterpulsation therapy improves quality of life and functional class of angina and dyspnoea in patients with refractory angina and becomes a non-invasive, safe and efficient procedure.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Angina]]></kwd>
<kwd lng="es"><![CDATA[Cardiopatía isquémica]]></kwd>
<kwd lng="es"><![CDATA[Enfermedad coronaria]]></kwd>
<kwd lng="es"><![CDATA[Calidad de vida]]></kwd>
<kwd lng="en"><![CDATA[Angina]]></kwd>
<kwd lng="en"><![CDATA[Ischemic heart disease]]></kwd>
<kwd lng="en"><![CDATA[Coronary disease]]></kwd>
<kwd lng="en"><![CDATA[Quality of life]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mendoza]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Isaza]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Beltrán]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Jaramillo]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Guías Colombianas de Cardiología, Síndrome Coronario Agudo sin Elevación del ST]]></article-title>
<source><![CDATA[Rev. Col. Cardiol]]></source>
<year>2008</year>
<numero>^s3</numero>
<issue>^s3</issue>
<supplement>3</supplement>
<page-range>145-232</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="book">
<collab>Sistema General de Seguridad Social en Salud - Colombia</collab>
<source><![CDATA[Guía de Práctica Clínica para el Síndrome Coronario Agudo]]></source>
<year>2013</year>
<publisher-loc><![CDATA[Colciencias - MinSalud ]]></publisher-loc>
<publisher-name><![CDATA[Centro Nacional de Investigación y Tecnologías en Salud, CINETS]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Guía de práctica clínica para pacientes con diagnóstico de síndrome coronario agudo: atención inicial y revascularización]]></article-title>
<source><![CDATA[Rev. Col. Cardiol]]></source>
<year>2013</year>
<numero>^s20</numero>
<issue>^s20</issue>
<supplement>20</supplement>
<page-range>45-85</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Montalescot]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Sechtem]]></surname>
</name>
<name>
<surname><![CDATA[Achenbach]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Andreotti]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Arden]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Budaj]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Guía de práctica clínica de la Sociedad Europea de Cardiología 2013, sobre diagnóstico y tratamiento de la cardiopatía isquémica estable]]></article-title>
<source><![CDATA[Rev. Esp. Cardiol.]]></source>
<year>2014</year>
<volume>67</volume>
<page-range>135e1-81e</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fihn]]></surname>
<given-names><![CDATA[SD]]></given-names>
</name>
<name>
<surname><![CDATA[Gardian]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Abrams]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Berra]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Blanfenship]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
<name>
<surname><![CDATA[Dallas]]></surname>
<given-names><![CDATA[AP]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the diagnosis and management of patients with stable ischemic heart disease a report of the American College of Cardiology Foundation/American Heart Association Task Force on, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons]]></article-title>
<source><![CDATA[J Am Coll Cardiol]]></source>
<year>2012</year>
<volume>60</volume>
<page-range>e44-164</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[López - Sendón]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Castro]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Angina estable, guías de tratamiento]]></article-title>
<source><![CDATA[Rev. Esp. Cardiol]]></source>
<year>2010</year>
<volume>10</volume>
<page-range>22B-30B</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[McGillion]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Arthur]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Cook]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Carroll]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Víctor]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[V Allier]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Management of patients with refractory angina Canadian Cardiovascular Society/Canadian Pain Society Joint Guidelines.]]></article-title>
<collab>&lt; ELAL&gt;</collab>
<source><![CDATA[Canadian Journal of Cardiology]]></source>
<year>2012</year>
<volume>28</volume>
<page-range>S20-41</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kones]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Recent advances in the management of chronic stable angina II Anti - ischemic therapy, options for refractory angina, risk factor reduction, and revascularization]]></article-title>
<source><![CDATA[Vascular Health and Risk Management]]></source>
<year>2010</year>
<volume>6</volume>
<page-range>749-74</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Soran]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Alternative therapy for medically refractory angina Enhanced external counterpulsation and transmyocardial laser revascularization. Cardiol]]></article-title>
<source><![CDATA[Clin]]></source>
<year>2014</year>
<volume>32</volume>
<page-range>429-38</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Badia]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Roset]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Montserrat]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Herdman]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Segura]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[La versión española del EuroQol descripción y aplicaciones. Med]]></article-title>
<source><![CDATA[Clin. (Barc.)]]></source>
<year>1999</year>
<numero>^s1</numero>
<issue>^s1</issue>
<supplement>1</supplement>
<page-range>79-86</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Boden]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[O Rourke]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Teo]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Hartigan]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Maron]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Kostuk]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[For the COURAGE Trial Research Group Optimal Medical therapy with or without PCI for stable coronary disease.]]></article-title>
<source><![CDATA[N. Engl. J. Med.]]></source>
<year>2007</year>
<volume>356</volume>
<page-range>1503-16</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Arora]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Chou]]></surname>
<given-names><![CDATA[TM]]></given-names>
</name>
<name>
<surname><![CDATA[Jain]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Fleishman]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Crawford]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[McKierman]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The Multicenter Study of Enhanced External Counterpulsation (MUST - EECP) Effect of EECP on Exercise - induced Myocardial Ischemia and Angina Episodes]]></article-title>
<source><![CDATA[J. Am. Coll Cardiol.]]></source>
<year>1999</year>
<volume>33</volume>
<page-range>1833-40</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lawson]]></surname>
<given-names><![CDATA[WE]]></given-names>
</name>
<name>
<surname><![CDATA[Hui]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
<name>
<surname><![CDATA[Cohn]]></surname>
<given-names><![CDATA[PF]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Long - term prognosis of patients with angina treated with enhanced external counterpulsation five - year follow - up study.]]></article-title>
<source><![CDATA[Clin. Cardiol.]]></source>
<year>2000</year>
<volume>23</volume>
<page-range>254-8</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Loh]]></surname>
<given-names><![CDATA[PH]]></given-names>
</name>
<name>
<surname><![CDATA[Cleland]]></surname>
<given-names><![CDATA[JG]]></given-names>
</name>
<name>
<surname><![CDATA[Louis]]></surname>
<given-names><![CDATA[AA]]></given-names>
</name>
<name>
<surname><![CDATA[Kennard]]></surname>
<given-names><![CDATA[ED]]></given-names>
</name>
<name>
<surname><![CDATA[Cook]]></surname>
<given-names><![CDATA[JF]]></given-names>
</name>
<name>
<surname><![CDATA[Caplin]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Enhanced external counterpulsation in the treatment of chronic refractory angina a long -term follow- up outcome from the International Enhanced External Counterpulsation Patient Registry]]></article-title>
<source><![CDATA[Clin. Cardiol.]]></source>
<year>2008</year>
<volume>31</volume>
<page-range>159-64</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Braverman]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Enhanced external counterpulsation A novel therapy for angina]]></article-title>
<source><![CDATA[Complementary Therapies in Clinical Practice]]></source>
<year>2012</year>
<volume>18</volume>
<page-range>197-203</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lawson]]></surname>
<given-names><![CDATA[WE]]></given-names>
</name>
<name>
<surname><![CDATA[Hui]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
<name>
<surname><![CDATA[Kennard]]></surname>
<given-names><![CDATA[ED]]></given-names>
</name>
<name>
<surname><![CDATA[Kelsey]]></surname>
<given-names><![CDATA[SF]]></given-names>
</name>
<name>
<surname><![CDATA[Michaels]]></surname>
<given-names><![CDATA[AD]]></given-names>
</name>
<name>
<surname><![CDATA[Soran]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[International Enhanced External Counterpulsation Patient Registry Investigators Two - year outcomes in patients with mild refractory angina treated with enhanced external counterpulsation]]></article-title>
<source><![CDATA[Clin. Cardiol.]]></source>
<year>2006</year>
<volume>29</volume>
<page-range>69-73</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Soran]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Kennard]]></surname>
<given-names><![CDATA[ED]]></given-names>
</name>
<name>
<surname><![CDATA[Bart]]></surname>
<given-names><![CDATA[BA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Impact of external counterpulsation treatment on emergency department visits and hospitalizations in refractory angina patients with left ventricular dysfunction Congest]]></article-title>
<collab>on behalf of IEPR Investigators</collab>
<source><![CDATA[Heart Fail]]></source>
<year>2007</year>
<volume>13</volume>
<page-range>36-40</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Soran]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Kennard]]></surname>
<given-names><![CDATA[ED]]></given-names>
</name>
<name>
<surname><![CDATA[Kfoury]]></surname>
<given-names><![CDATA[AG]]></given-names>
</name>
<name>
<surname><![CDATA[Kelsey]]></surname>
<given-names><![CDATA[SF]]></given-names>
</name>
</person-group>
<collab>IEPR Investigators</collab>
<article-title xml:lang=""><![CDATA[International EECP Patient Registry Investigators Two years clinical outcomes after enhanced external counterpulsation (EECP) therapy in patients with refractory angina pectoris and left ventricular dysfunction (Report from the International EECP Patient Registry).]]></article-title>
<source><![CDATA[Am J. Cardiol]]></source>
<year>2006</year>
<volume>97</volume>
<page-range>17-20</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Manchada]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Soran]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Enhanced External Counterpulsation and future directions Step beyond medical management for patients with angina and heart failure]]></article-title>
<source><![CDATA[J Am Coll Cardiol]]></source>
<year>2007</year>
<volume>50</volume>
<page-range>1523-31</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Urano]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Ikeda]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Ueno]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Matsumoto]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Murohara]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Imaizumi]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Enhanced External Counterpulsation improves exercise tolerance, reduces exercise - Induced myocardial ischemia and improves left ventricular diastolic filling in patients with coronary artery disease]]></article-title>
<source><![CDATA[J. Am Coll Cardiol]]></source>
<year>2001</year>
<volume>37</volume>
<page-range>93-9</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Taguchi]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Ogawa]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Kanaya]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Matsuda]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Kuga]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Nakatsugawa]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effects of Enhanced External Counterpulsation on Hemodynamics and Its Mechanism - Relation to neurohumoral factors]]></article-title>
<source><![CDATA[Circ. J]]></source>
<year>2004</year>
<volume>68</volume>
<page-range>1030-4</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yang]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Wu]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Vasculoprotective properties of enhanced external counterpulsation for coronary artery disease beyond the hemodynamics]]></article-title>
<source><![CDATA[International Journal of Cardiology]]></source>
<year>2013</year>
<volume>166</volume>
<page-range>38-43</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Manchanda]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Aggarwal]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Aggarwal]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Soran]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Management of refractory angina pectoris]]></article-title>
<source><![CDATA[Cardiol]]></source>
<year>2011</year>
<volume>18</volume>
<page-range>343-51</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Braith]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Conti]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Nichols]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Choi]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Khuddus]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Beck]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Enhanced External Counterpulsation Improves peripheral artery flow - mediated dilation in patients with chronic angina A Randomized Sham - Controlled Study]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2010</year>
<volume>122</volume>
<page-range>1612-20</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Michaels]]></surname>
<given-names><![CDATA[AD]]></given-names>
</name>
<name>
<surname><![CDATA[Accad]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Ports]]></surname>
<given-names><![CDATA[TA]]></given-names>
</name>
<name>
<surname><![CDATA[Grossman]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Left ventricular systolic unloading and augmentation of intracoronary pressure and Doppler flow during enhanced external counterpulsation]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2002</year>
<volume>106</volume>
<page-range>1237-42</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
